News

RadioMedix appointed Dr.Ferey Faridian as new member of the Board of Director

Posted by RadioMedix . on

RadioMedix appointed Dr.Ferey Faridian as new member of the Board of Director

Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors. “It is an honor to join the world-class team at Radiomedix to guide in the areas of strategy and finance at a time when the company is at the brink of creating new treatment modalities in neuroendocrine cancers, said Faridian.” Faridian is a partner at Newport LLC, a nationwide business advisory firm of experienced CEOs and executives helping middle-market companies...

Read more →

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Posted by on

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Houston, TX and St. Louis, MO, Sept. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that DetectnetTM (copper Cu 64 dotatate injection) was approved by the U.S. Food and Drug Administration (FDA).  Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.  Curium expects to launch Detectnet immediately with doses available through various nuclear pharmacies or directly from Curium.    “Detectnet brings an exciting advancement in the diagnosis of neuroendocrine tumors for healthcare providers, patients, and their caregivers,” said Ebrahim Delpassand, MD, CEO...

Read more →

ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market

Posted by RadioMedix . on

ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market

ITM’s long-term partner RadioMedix is producing and distributing GeGant® for the U.S. market GARCHING, Germany & MUNICH & HOUSTON--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, announced today that ITM has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for ITM’s next generation Germanium-68/Gallium-68 (68Ge/68Ga) Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant®. The RadioMedix Spica Center is a 21 CFR 211 compliant, and GMP radiopharmaceutical manufacturing facility...

Read more →

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada

Posted by RadioMedix . on

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada

Houston, TX, USA and  Garching, Germany. RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada. The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators can be used for radiolabeling reactions or directly as a high dose liquid radioactive source. Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the W/Re-188 Generator. Re-188 has shown high efficiency and value for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology areas. Its advantageous physical properties, its potential low cost, and with a long-lived parent, make this generator an...

Read more →

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

Posted by RadioMedix . on

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

Houston and St Louis, Jan. 07, 2020 (GLOBE NEWSWIRE) — RadioMedix Inc. and its commercial partner Curium announced today that the New Drug Application for copper Cu 64 dotatate injection was filed with the U.S. Food and Drug Administration (FDA). Copper Cu 64 dotatate injection is a PET diagnostic agent intended for somatostatin receptor (SSTR) expressing neuroendocrine tumors (NETs). The FDA previously granted Fast Track designation to copper Cu 64 dotatate injection. “If approved, we expect that copper Cu 64 dotatate injection will be the first FDA approved Cu 64 labeled radiopharmaceutical for PET/CT imaging. In addition, this drug will...

Read more →